Damien Kee

4.7k total citations · 1 hit paper
43 papers, 1.2k citations indexed

About

Damien Kee is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Damien Kee has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Damien Kee's work include Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (9 papers) and Melanoma and MAPK Pathways (8 papers). Damien Kee is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (9 papers) and Melanoma and MAPK Pathways (8 papers). Damien Kee collaborates with scholars based in Australia, United States and New Zealand. Damien Kee's co-authors include Grant A. McArthur, Jonathan Cebon, Oliver Klein, Matteo S. Carlino, Ben Markman, Jodie Palmer, Andreas Behren, Craig Underhill, Michael Michael and Louise Jackett and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Damien Kee

38 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A gut microbial signature for combination immune checkpoint blockade across cancer types

2024 67 citations Ashray Gunjur, Yan Shao et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Damien Kee Australia	14	879	579	223	177	153	43	1.2k
Eduard Gasal United States	16	1.0k 1.1×	720 1.2×	306 1.4×	57 0.3×	319 2.1×	45	1.5k
Cécile Pagès France	19	794 0.9×	302 0.5×	85 0.4×	188 1.1×	190 1.2×	53	1.1k
Vijay Peddareddigari United States	11	600 0.7×	714 1.2×	149 0.7×	46 0.3×	183 1.2×	18	1.2k
J. J. Bonerandi France	14	783 0.9×	464 0.8×	106 0.5×	292 1.6×	342 2.2×	25	1.4k
Ryota Tanaka Japan	21	1.0k 1.2×	311 0.5×	121 0.5×	225 1.3×	247 1.6×	71	1.4k
Yanina Jansen Belgium	15	595 0.7×	345 0.6×	77 0.3×	88 0.5×	156 1.0×	48	887
Lucia Festino Italy	18	880 1.0×	368 0.6×	99 0.4×	69 0.4×	190 1.2×	39	1.2k
Trina Lum Australia	17	605 0.7×	330 0.6×	235 1.1×	54 0.3×	240 1.6×	26	964
Zachary R. Chalmers United States	15	584 0.7×	649 1.1×	152 0.7×	148 0.8×	580 3.8×	35	1.4k
Vito Vanella Italy	16	709 0.8×	328 0.6×	86 0.4×	58 0.3×	145 0.9×	34	997

Countries citing papers authored by Damien Kee

Since Specialization

Citations

This map shows the geographic impact of Damien Kee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damien Kee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damien Kee more than expected).

Fields of papers citing papers by Damien Kee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damien Kee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damien Kee. The network helps show where Damien Kee may publish in the future.

Co-authorship network of co-authors of Damien Kee

This figure shows the co-authorship network connecting the top 25 collaborators of Damien Kee. A scholar is included among the top collaborators of Damien Kee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damien Kee. Damien Kee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luckett, Tim, et al.. (2025). Uncertainty and hope in people with metastatic uveal melanoma in the era of immunotherapy and targeted treatments: a theory-based qualitative study. BMC Cancer. 25(1). 939–939.

Ghaus, Aisha, Mark Shackleton, Damien Kee, et al.. (2025). Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review. Clinical and Experimental Ophthalmology. 54(1). 99–112.

Klein, Oliver, Matteo S. Carlino, Craig Underhill, et al.. (2024). 713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial. Annals of Oncology. 35. S546–S547. 5 indexed citations

Gunjur, Ashray, Yan Shao, Oliver Klein, et al.. (2024). A gut microbial signature for combination immune checkpoint blockade across cancer types. Nature Medicine. 30(3). 797–809. 67 indexed citations breakdown →

Klein, Oliver, Matteo S. Carlino, Michelle Brown, et al.. (2024). 282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer. Annals of Oncology. 35. S119–S119. 2 indexed citations

Klein, Oliver, Bo Gao, Henry Chan, et al.. (2024). 998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study. Annals of Oncology. 35. S679–S680. 1 indexed citations

Lee, Sze-Ting, et al.. (2024). Positron Emission Tomography/Computed Tomography Transformation of Oncology. PET Clinics. 19(2). 231–248. 1 indexed citations

Luckett, Tim, et al.. (2024). What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life. Melanoma Research. 34(3). 248–257. 2 indexed citations

Long, Georgina V., Catriona M. McNeil, Antoni Ribas, et al.. (2024). Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals of Oncology. 35(12). 1191–1199. 33 indexed citations

10.

Robert, Caroline, Matteo S. Carlino, Catriona M. McNeil, et al.. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 41(24). 3998–4003. 63 indexed citations

11.

Salama, April K.S., Jens T. Siveke, Alfonso Berrocal, et al.. (2021). 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma. Annals of Oncology. 32. S855–S855. 3 indexed citations

12.

Klein, Oliver, Damien Kee, Ben Markman, et al.. (2020). Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research. 26(17). 4454–4459. 116 indexed citations

13.

Iravani, Amir, Medhat Osman, Alison M. Weppler, et al.. (2020). FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2776–2786. 49 indexed citations

14.

Gunjur, Ashray, Oliver Klein, Damien Kee, & Jonathan Cebon. (2019). Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. Journal for ImmunoTherapy of Cancer. 7(1). 241–241. 20 indexed citations

15.

Porubský, Štefan, Peter J. Jessup, Damien Kee, et al.. (2019). Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 476(2). 323–327. 1 indexed citations

16.

Kim, Sung‐Bum, et al.. (2016). Stereotactic guidance for navigated percutaneous sacroiliac joint fusion. Journal of Biomedical Research. 30(2). 162–162. 13 indexed citations

17.

Kee, Damien & Grant A. McArthur. (2016). Immunotherapy of melanoma. European Journal of Surgical Oncology. 43(3). 594–603. 21 indexed citations

18.

Kee, Damien & Grant A. McArthur. (2014). Targeted Therapies for Cutaneous Melanoma. Hematology/Oncology Clinics of North America. 28(3). 491–505. 10 indexed citations

19.

Ribas, Antoni, René González, Anna C. Pavlick, et al.. (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. The Lancet Oncology. 15(9). 954–965. 201 indexed citations

20.

Oberholzer, Patrick A., Damien Kee, Piotr Dziunycz, et al.. (2011). RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology. 30(3). 316–321. 298 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact